Steven M. Horwitz, MD
Lymphoma Specialist & Cellular Therapist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- T Cell Lymphomas
- Cutaneous (Skin) Lymphomas
- Other non-Hodgkin and Hodgkin Lymphomas
Request an Appointment
About Me
- Endowed Chair, The Nonna’s Garden Foundation Chair, With Gratitude to Memorial Sloan Kettering
I am a medical oncologist who focuses on the care of patients with lymphoma, and I have clinical expertise in all types of lymphomas. My research is aimed at developing an improved understanding of new therapies for patients with several less-common types of lymphoma, including T cell lymphomas, cutaneous (skin) lymphomas, Hodgkin disease, and lymphomas in immunosuppressed patients after organ transplant (post-transplant lymphoproliferative disorders or PTLD).
A lymphoma specialist is a doctor with special training in diagnosing and treating lymphoma.
A cellular therapy specialist is a doctor with special training in using cell therapies to treat health conditions such as cancer. Therapies can include chimeric antigen receptor (CAR) T cell therapy.
My Specialties
- T Cell Lymphomas
- Cutaneous (Skin) Lymphomas
- Other non-Hodgkin and Hodgkin Lymphomas
Education
- MD, Case Western Reserve University
Residencies
- Internal Medicine - University of Rochester/Strong Memorial Hospital
Awards and Honors
- Castle Connolly: America’s Top Doctor (2024)
- Top Doctors New York Metro Area, Castle Connolly (2023)
- Castle Connolly: America's Top Doctors (2023)
- Castle Connolly: New York Magazine Top Doctors (2013-2021)
Fellowships
- Medicine - Stanford University Medical Center
Board Certifications
- Internal Medicine
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Horwitz sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Clinical Trials
- Clinical Trials Investigated by Dr. Horwitz
- A Phase I Study Assessing the Addition of Lenalidomide to the Usual Combination Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma
- A Phase I/II Study of CFT7455 in People with Non-Hodgkin Lymphoma or Multiple Myeloma
- Clinical Trials Co-Investigated by Dr. Horwitz
- A Phase 1 Study of SGN-35T in People with Lymphoma
- A Phase 2 Study of AFM13 Plus AB-101 To Treat Hodgkin Lymphoma and Peripheral T-Cell Lymphoma
Read more
- A Phase 2 Study of Ruxolitinib in People With T-Cell Large Granular Lymphocytic Leukemia
- A Phase I Study of KT-333 in People with Lymphoma and Large Granular Lymphocytic Leukemia
- A Phase I Study of ONO-4685 Immunotherapy in People with T-Cell Lymphoma
- A Phase II Study Assessing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
- A Phase II Study of Pembrolizumab Immunotherapy plus Gemcitabine to Treat Advanced Mycosis Fungoides or Sézary Syndrome
- A Phase II Study of Ruxolitinib in Patients with Persistent or Recurrent T-Cell or NK-Cell Lymphoma
- A Phase II Study to Determine the Optimal Dose of Brentuximab Vedotin for Mycosis Fungoides and Lymphomatoid Papulosis
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Horwitz’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Steven M. Horwitz discloses the following relationships and financial interests:
-
Abcuro, Inc.
Professional Services and Activities -
Clinical Education Alliance, LLC
Professional Services and Activities -
Corvus Pharmaceuticals, Inc.
Professional Services and Activities -
CTI BioPharma Corp.
Professional Services and Activities -
Cutaneous Lymphoma Foundation
Fiduciary Role / Position -
Daiichi Sankyo
Professional Services and Activities -
DKMS
Fiduciary Role / Position -
Dren Bio
Professional Services and Activities -
Farallon Capital Management, L.L.C.
Professional Services and Activities -
International Lymphoma Conference
Professional Services and Activities -
International Society for Cutaneous Lymphomas
Fiduciary Role / Position -
Kyowa Hakko Kirin Pharma
Professional Services and Activities -
March Biosciences, Inc.
Professional Services and Activities (Uncompensated)
-
National Comprehensive Cancer Network
Fiduciary Role / Position -
Neovii Pharmaceuticals AG
Professional Services and Activities (Uncompensated) -
New York Oncology Hematology
Professional Services and Activities -
Ono Pharma
Professional Services and Activities -
Pfizer, Inc.
Professional Services and Activities -
Physicians' Education Resource
Professional Services and Activities -
Seagen
Professional Services and Activities -
Society of Hematologic Oncology
Professional Services and Activities -
SymBio Pharmaceuticals Limited
Professional Services and Activities -
Takeda Pharmaceuticals
Professional Services and Activities -
Treeline Biosciences, Inc.
Professional Services and Activities (Uncompensated) -
UptoDate
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].